Diagnostic accuracy of the Fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liver disease with type 2 diabetes: A systematic review and meta-analysis
4
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The Fibrosis-4 index (FIB-4) is a noninvasive test widely used to rule out advanced liver fibrosis (AF) in patients with nonalcoholic fatty liver disease (NAFLD). However, its diagnostic accuracy in NAFLD patients with type 2 diabetes mellitus (T2DM) is controversial due to the high prevalence of AF in this population. Methods: Research focusing on the diagnostic accuracy of FIB-4 for liver fibrosis as validated by liver histology in NAFLD patients with T2DM was included, and 12 studies (n=5,624) were finally included in the meta-analysis. Sensitivity, specificity, hierarchical summary receiver operating characteristic (HSROC), positive predictive values (PPVs), and negative predictive values (NPVs) at low cutoffs (1.3–1.67) and high cutoffs (2.67–3.25) for ruling in and out AF were calculated. Results: At low cutoffs, the meta-analysis revealed a sensitivity of 0.74, specificity of 0.62, and HSROC of 0.75. At high cutoffs, the analysis showed a sensitivity of 0.33, specificity of 0.92, and HSROC of 0.85, suggesting FIB-4 as useful for identifying or excluding AF. In subgroup analyses, high mean age and F3 prevalence were associated with lower sensitivity. The calculated NPV and PPV were 0.82 and 0.49 at low cutoffs, whereas the NPV was 0.28 and the PPV was 0.70 at high cutoffs. There were insufficient estimated NPVs <0.90 at a hypothesized prevalence of AF >30% at an FIB-4 cutoff range of 1.3–1.67. Conclusions: Collectively, FIB-4 has moderate diagnostic accuracy for identifying or excluding AF in NAFLD patients with T2DM, but more evidence must be accumulated due to the limited number of currently reported studies and their heterogeneity.
Abstract
Background/Aims: The Fibrosis-4 index (FIB-4) is a noninvasive test widely used to rule out advanced liver fibrosis (AF) in patients with nonalcoholic fatty liver disease (NAFLD). However, its diagnostic accuracy in NAFLD patients with type 2 diabetes mellitus (T2DM) is controversial due to the high prevalence of AF in this population. Methods: Research focusing on the diagnostic accuracy of FIB-4 for liver fibrosis as validated by liver histology in NAFLD patients with T2DM was included, and 12 studies (n=5,624) were finally included in the meta-analysis. Sensitivity, specificity, hierarchical summary receiver operating characteristic (HSROC), positive predictive values (PPVs), and negative predictive values (NPVs) at low cutoffs (1.3–1.67) and high cutoffs (2.67–3.25) for ruling in and out AF were calculated. Results: At low cutoffs, the meta-analysis revealed a sensitivity of 0.74, specificity of 0.62, and HSROC of 0.75. At high cutoffs, the analysis showed a sensitivity of 0.33, specificity of 0.92, and HSROC of 0.85, suggesting FIB-4 as useful for identifying or excluding AF. In subgroup analyses, high mean age and F3 prevalence were associated with lower sensitivity. The calculated NPV and PPV were 0.82 and 0.49 at low cutoffs, whereas the NPV was 0.28 and the PPV was 0.70 at high cutoffs. There were insufficient estimated NPVs <0.90 at a hypothesized prevalence of AF >30% at an FIB-4 cutoff range of 1.3–1.67. Conclusions: Collectively, FIB-4 has moderate diagnostic accuracy for identifying or excluding AF in NAFLD patients with T2DM, but more evidence must be accumulated due to the limited number of currently reported studies and their heterogeneity.
참고문헌 (28)
- Sterling RK, "Development of a simple noninvasive index to predict significant fibrosis in patients with HIV", HCV coinfection, 2006, pp.43, 1317~1325
- McPherson S, "Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease", Gut, 59, pp.1265~1269 (2010)
- Stern C, "Identification of high-risk subjects in nonalcoholic fatty liver disease", Clin Mol Hepatol, 29(Suppl), pp.S196~S206 (2023)
- Reinson T, "Noninvasive serum biomarkers for liver fibrosis in NAFLD : current and future", Clin Mol Hepatol, 29(Suppl), pp.S157~S170 (2023)
- Huang DQ, "Fibrosis progression rate in biopsy-proven nonalcoholic fatty liver disease among people with diabetes versus people without diabetes : A multicenter study", Gastroenterology, 165, pp.463~472 (2023)
- Boursier J, "Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events", J Hepatol, 76, pp.1013~1020 (2022)
- Gracen L, "Low accuracy of FIB-4 test to identify people with diabetes at low risk of advanced fibrosis", J Hepatol, 77, pp.1219~1221 (2022)
- Rinella ME, "AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease", Hepatology, 77, pp.1797~1835 (2023)
- Pennisi G, "Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease(NAFLD)and type 2 diabetes", Hepatology, 78, pp.195~211 (2023)
- Kim GA, "Critical appraisal of metabolic dysfunction-associated steatotic liver disease : Implication of Janus-faced modernity", Clin Mol Hepatol, 29, pp.831~843 (2023)
- Whiting P, "The development of QUADAS : a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews", BMC Med Res Methodol, 3, pp.25~ (2003)
- Bertot LC, "Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease", Liver Int, 38, pp.1793~1802 (2018)
- Bril F, "Use of plasma fragments of propeptides of type III, V, and VI procollagen for the detection of liver fibrosis in type 2diabetes", Diabetes Care, 42, pp.1348~1351 (2019)
- Alkayyali T, "Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus : a study in biopsy-proven non-alcoholic fatty liver disease", Acta Diabetol, 57, pp.613~618 (2020)
- Bril F, "Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes", Diabetes Care, 43, pp.290~297 (2020)
- Ishiba H, "Type IV collagen 7S is the most accurate test for identifying advanced fibrosis in NAFLD with type 2 diabetes", Hepatol Commun, 5, pp.559~572 (2020)
- Singh A, "Accuracy of noninvasive fibrosis scores to detect advanced fibrosis in patients with type-2 diabetes with biopsyproven nonalcoholic fatty liver disease", J Clin Gastroenterol, 54, pp.891~897 (2020)
- Bril F, "Assessing strategies to target screening for advanced liver fibrosis among overweight and obese patients", Metab Target Organ Damage, 2, pp.11~ (2022)
- Ajmera V, "A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes", J Hepatol, 78, pp.471~478 (2023)
- Boursier J, "Impact of type 2 diabetes on the accuracy of noninvasive tests of liver fibrosis with resulting clinical implications", Clin Gastroenterol Hepatol, 21, pp.1243~1251 (2023)
- Castera L, "High prevalence of NASH and advanced fibrosis in type 2 diabetes : A prospective study of 330outpatients undergoing liver biopsies for elevated ALT, using a low threshold", Diabetes Care, 46, pp.1354~1362 (2023)
- Singh A, "Diabetes liver fibrosis score to detect advanced fibrosis in diabetics with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 20, pp.e624~e626 (2022)
- Han S, "Accuracy of noninvasive scoring systems in assessing liver fibrosis in patients with nonalcoholic fatty liver disease : A systematic review and meta-analysis", Gut Liver, 16, pp.952~963 (2022)
- American Diabetes Association Professional Practice Committee, "4. Comprehensive medical evaluation and assessment of comorbidities : Standards of care in diabetes-2024", Diabetes Care, 47(Suppl 1), pp.S52~S76 (2024)
- Archer AJ, "EASL clinical practice guidelines : non-invasive liver tests for evaluation of liver disease severity and prognosis", Frontline Gastroenterol, 13, pp.436~439 (2022)
- Bazick J, "Clinical model for NASH and advanced fibrosis in adult patients with diabetes and NAFLD : Guidelines for Referral in NAFLD", Diabetes Care, 38, pp.1347~1355 (2015)
- Moon SY, "Proposal of a novel serological algorithm combining FIB-4 and serum M2BPGi for advanced fibrosis in nonalcoholic fatty liver disease", Gut Liver, 18, pp.283~293 (2024)
- Mózes FE, "Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD : an individual patient data meta-analysis", Gut, 71, pp.1006~1019 (2022)